SCHEMBL2118685

SCHEMBL2118685

Cc1ccc(-c2cnco2)cc1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
PSEN1 P49768 1/20 0.57
PSEN2 P49810 1/20 0.57
APH1B Q8WW43 1/20 0.57
NCSTN Q92542 1/20 0.57
APH1A Q96BI3 1/20 0.57
PSENEN Q9NZ42 1/20 0.57
CCR9 P51686 5/20 0.56
MAPT P10636 3/20 0.52
TP53 P04637 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NOTUM Q6P988 1/20 0.51
ALDH1A1 P00352 1/20 0.51
KMT2A Q03164 2/20 0.51
DRD2 P14416 1/20 0.48
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
DRD3 P35462 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120014 0.88 POLB (0.51) POLBCYP3A4CYP2D6PSEN1PSEN2
SCHEMBL2121436 0.88 POLB (0.51) POLBCYP3A4CYP2D6PSEN1PSEN2
SCHEMBL2119292 0.85 CCR9 (0.48) POLBCYP3A4CYP2D6PSEN1PSEN2
SCHEMBL2119257 0.83 POLB (0.48) POLBCYP3A4CYP2D6PSEN1PSEN2
SCHEMBL2118524 0.82 TRIM24 (0.57) POLBCYP3A4MAPTTP53SMN1; SMN2
SCHEMBL2121588 0.81 CYP3A4 (0.46) POLBCYP3A4CYP2D6PSEN1PSEN2
SCHEMBL2119449 0.81 CYP3A4 (0.46) POLBCYP3A4CYP2D6PSEN1PSEN2
SCHEMBL2117458 0.81 POLB (0.54) POLBMAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL2117617 0.81 CYP3A4 (0.46) POLBCYP3A4CYP2D6PSEN1PSEN2
SCHEMBL2118369 0.80 ALDH1A1 (0.56) POLBCYP3A4CYP2D6PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 POLB 817/4885CYP3A4 3761/4885CYP2D6 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.